Chronic Heart Failure: Developments and Perspectives

Factors Associated With Major Complications and Mortality During Hospitalization in Patients With Ankylosing Spondylitis Undergoing Surgical Management for a Spine Fracture

STUDY DESIGN

Retrospective study.

OBJECTIVES

To analyze factors associated with major complications (MC) in patients with ankylosing spondylitis (AS) undergoing surgical management for a spine fracture.

METHODS

Included were all persons with spine fractures and AS in a teriary health care center between 2003 and 2019. Clinical data and MC were characterized with descriptive characteristics. Multivariable analyses were used to find factors associated with MC.

RESULTS

In total, 174 traumatic fracture incidents in 166 patients with AS were included, with a mean patient age of 70.7 ± 13.1 years. The main reason for spine fracture was minor trauma (79.9%). Spinal cord injuries (SCI) were described in 36.7% of cases. The majority of patients (54.6%) showed more than one fracture of the spine, with cervical fractures being the most common (50.5%). Overall, the incidences of surgical site infection, implant failure, nosocomial pneumonia (NP), and mortality were 17.2%, 9.2%, 31%, and 14.9%, respectively. ICU stay > 48 hours was associated with MC (including death). Posterior approach for spondylodesis, ICU stay > 48 hours and cervical SCI were related to MC (excluding death). Age > 70 years, NP and Charlson comorbidity index > 5 points were associated with in-hospital mortality.

CONCLUSIONS

Patients with AS and surgical treatment of spine fractures are at high risk for MC. Therefore, our results might give physicians better insight into the incidence and sequelae of major complications and therefore might improve patient and family expectations.

Pharmacotherapy Implications of Revised Chronic Heart Failure Guidelines

OBJECTIVE

To provide an overview of major drug therapy recommendations within recently revised chronic heart failure (CHF)guidelines.

DATA SOURCES

Guideline statements and English-language articles from MEDLINE pertinent to CHF.

STUDY SELECTION AND DATA EXTRACTION

Recently published guidelines from the American College of Cardiology (ACC)/American Heart Association (AHA) and the Heart Failure Society of America (HFSA) served as the focus of this review. Prospective comparative trials, review articles, and editorials were also considered.

DATA SYNTHESIS

Recommendations within the ACC/AHA and HFSA guidelines continue to provide a systematic, evidence-based approach regarding CHF management. The HFSA guidelines recommend that the severity of clinical disease and functional limitation be characterized using the New York Heart association (NYHA) functional classification system. A key feature of the ACC/AHA guidelines is the use of a staging system that recognizes the development and progression of heart failure. Both guidelines stress the importance of neurohormonal blockade with angiotensin-converting enzyme inhibitors and beta-adrenergic blockers. Moreover, the guidelines expand the role of aldosterone antagonists, angiotensin II receptor blockers, and hydralazine/isosorbide dinitrate, particularly in combination with standard treatments. Diuretics and digoxin remain symptomatic treatments only.

CONCLUSIONS

This article summarizes key drug therapy recommendations from the revised ACC/AHA and HFSA guideline statements. Pharmacists caring for CHF patients should be familiar with these recommendations and aid in their implementation.

Anaesthesia and cardiac contractility modulation

Chronic heart failure is known to be an important risk factor for adverse perioperative outcome in patients undergoing non-cardiac surgery. A promising new form of electric therapy is currently being used in a phase III trial in patients with severe chronic heart failure (cardiac contractility modulation). Cardiac contractility modulation is a non-pharmacological approach to improve Ca2+ effect on cardiac myofilaments using electric currents. The cardiac contractility modulation system used at present (OPTIMIZER III, Impulse Dynamics, Orangeburg, NY, USA) consists of a subcutaneously implanted pulse generator and three electrodes. As far as we know, cardiac contractility modulation therapy is a safe and feasible way of improving the systolic function of the heart in congestive heart failure patients. No pro-arrhythmic effects of this new therapy have been reported. The technique shows promise as an additive treatment for severe chronic heart failure. The perioperative and intraoperative management of patients should follow current cardiac pacemaker/implantable cardioverter defibrillator guidelines.